Tissue | Expression Dynamics | Abbreviation |
Breast | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Breast/NPM1_pca_on_diff_genes.png) | IDC: Invasive ductal carcinoma |
DCIS: Ductal carcinoma in situ |
Precancer(BRCA1-mut): Precancerous lesion from BRCA1 mutation carriers |
Cervix | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Cervix/NPM1_pca_on_diff_genes.png) | CC: Cervix cancer |
HSIL_HPV: HPV-infected high-grade squamous intraepithelial lesions |
N_HPV: HPV-infected normal cervix |
Colorectum (GSE201348) | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Colorectum/Becker/NPM1_pca_on_diff_genes.png) | FAP: Familial adenomatous polyposis |
CRC: Colorectal cancer |
Colorectum (HTA11) | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Colorectum/Chen/NPM1_pca_on_diff_genes.png) | AD: Adenomas |
SER: Sessile serrated lesions |
MSI-H: Microsatellite-high colorectal cancer |
MSS: Microsatellite stable colorectal cancer |
Endometrium | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Endometrium/NPM1_pca_on_diff_genes.png) | AEH: Atypical endometrial hyperplasia |
EEC: Endometrioid Cancer |
Esophagus | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Esophagus/NPM1_pca_on_diff_genes.png) | ESCC: Esophageal squamous cell carcinoma |
HGIN: High-grade intraepithelial neoplasias |
LGIN: Low-grade intraepithelial neoplasias |
GC | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/GC/NPM1_pca_on_diff_genes.png) | CAG: Chronic atrophic gastritis |
CAG with IM: Chronic atrophic gastritis with intestinal metaplasia |
CSG: Chronic superficial gastritis |
GC: Gastric cancer |
SIM: Severe intestinal metaplasia |
WIM: Wild intestinal metaplasia |
Liver | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Liver/NPM1_pca_on_diff_genes.png) | HCC: Hepatocellular carcinoma |
NAFLD: Non-alcoholic fatty liver disease |
Lung | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Lung/NPM1_pca_on_diff_genes.png) | AAH: Atypical adenomatous hyperplasia |
AIS: Adenocarcinoma in situ |
IAC: Invasive lung adenocarcinoma |
MIA: Minimally invasive adenocarcinoma |
Oral Cavity | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/OralCavity/NPM1_pca_on_diff_genes.png) | EOLP: Erosive Oral lichen planus |
LP: leukoplakia |
NEOLP: Non-erosive oral lichen planus |
OSCC: Oral squamous cell carcinoma |
Prostate | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Prostate/NPM1_pca_on_diff_genes.png) | BPH: Benign Prostatic Hyperplasia |
Skin | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Skin/NPM1_pca_on_diff_genes.png) | AK: Actinic keratosis |
cSCC: Cutaneous squamous cell carcinoma |
SCCIS:squamous cell carcinoma in situ |
Thyroid | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Thyroid/NPM1_pca_on_diff_genes.png) | ATC: Anaplastic thyroid cancer |
HT: Hashimoto's thyroiditis |
PTC: Papillary thyroid cancer |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:003367427 | Thyroid | ATC | positive regulation of kinase activity | 212/6293 | 467/18723 | 5.89e-08 | 1.05e-06 | 212 |
GO:0006325110 | Thyroid | ATC | chromatin organization | 189/6293 | 409/18723 | 6.40e-08 | 1.13e-06 | 189 |
GO:190332218 | Thyroid | ATC | positive regulation of protein modification by small protein conjugation or removal | 77/6293 | 138/18723 | 6.67e-08 | 1.17e-06 | 77 |
GO:003139818 | Thyroid | ATC | positive regulation of protein ubiquitination | 67/6293 | 119/18723 | 2.95e-07 | 4.46e-06 | 67 |
GO:004277016 | Thyroid | ATC | signal transduction in response to DNA damage | 90/6293 | 172/18723 | 3.01e-07 | 4.52e-06 | 90 |
GO:003311935 | Thyroid | ATC | negative regulation of RNA splicing | 21/6293 | 25/18723 | 3.02e-07 | 4.52e-06 | 21 |
GO:003033033 | Thyroid | ATC | DNA damage response, signal transduction by p53 class mediator | 45/6293 | 72/18723 | 4.87e-07 | 7.03e-06 | 45 |
GO:000756924 | Thyroid | ATC | cell aging | 72/6293 | 132/18723 | 5.77e-07 | 8.15e-06 | 72 |
GO:005068623 | Thyroid | ATC | negative regulation of mRNA processing | 23/6293 | 29/18723 | 5.84e-07 | 8.19e-06 | 23 |
GO:007116614 | Thyroid | ATC | ribonucleoprotein complex localization | 47/6293 | 77/18723 | 7.43e-07 | 9.89e-06 | 47 |
GO:000640514 | Thyroid | ATC | RNA export from nucleus | 50/6293 | 84/18723 | 9.81e-07 | 1.29e-05 | 50 |
GO:009006817 | Thyroid | ATC | positive regulation of cell cycle process | 115/6293 | 236/18723 | 9.87e-07 | 1.29e-05 | 115 |
GO:003150316 | Thyroid | ATC | protein-containing complex localization | 108/6293 | 220/18723 | 1.33e-06 | 1.69e-05 | 108 |
GO:007142614 | Thyroid | ATC | ribonucleoprotein complex export from nucleus | 46/6293 | 76/18723 | 1.37e-06 | 1.71e-05 | 46 |
GO:1903312210 | Thyroid | ATC | negative regulation of mRNA metabolic process | 53/6293 | 92/18723 | 1.93e-06 | 2.32e-05 | 53 |
GO:004802532 | Thyroid | ATC | negative regulation of mRNA splicing, via spliceosome | 17/6293 | 20/18723 | 3.20e-06 | 3.62e-05 | 17 |
GO:003288613 | Thyroid | ATC | regulation of microtubule-based process | 114/6293 | 240/18723 | 5.17e-06 | 5.59e-05 | 114 |
GO:000836122 | Thyroid | ATC | regulation of cell size | 89/6293 | 181/18723 | 1.01e-05 | 1.00e-04 | 89 |
GO:004351631 | Thyroid | ATC | regulation of DNA damage response, signal transduction by p53 class mediator | 24/6293 | 34/18723 | 1.15e-05 | 1.12e-04 | 24 |
GO:001094813 | Thyroid | ATC | negative regulation of cell cycle process | 134/6293 | 294/18723 | 1.19e-05 | 1.15e-04 | 134 |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
4869 | NPM1 | CLINICALLY ACTIONABLE, DNA REPAIR, DRUGGABLE GENOME, DRUG RESISTANCE | | Crizotinib | CRIZOTINIB | 27009859,25749034,24509625,18089725,25421750 |
4869 | NPM1 | CLINICALLY ACTIONABLE, DNA REPAIR, DRUGGABLE GENOME, DRUG RESISTANCE | | IPP-204106 | | |
4869 | NPM1 | CLINICALLY ACTIONABLE, DNA REPAIR, DRUGGABLE GENOME, DRUG RESISTANCE | | N/A | | 19047294,26586702,16109776,26676635,26239249,25281355,24573385,25713434 |
4869 | NPM1 | CLINICALLY ACTIONABLE, DNA REPAIR, DRUGGABLE GENOME, DRUG RESISTANCE | | AZD3463 | | 27009859 |
4869 | NPM1 | CLINICALLY ACTIONABLE, DNA REPAIR, DRUGGABLE GENOME, DRUG RESISTANCE | | Deguelin | DEGUELIN | 25348016,25242579 |
4869 | NPM1 | CLINICALLY ACTIONABLE, DNA REPAIR, DRUGGABLE GENOME, DRUG RESISTANCE | | Venetoclax | VENETOCLAX | |
4869 | NPM1 | CLINICALLY ACTIONABLE, DNA REPAIR, DRUGGABLE GENOME, DRUG RESISTANCE | | EPZ004777 | | 27535106 |
4869 | NPM1 | CLINICALLY ACTIONABLE, DNA REPAIR, DRUGGABLE GENOME, DRUG RESISTANCE | | MI-503 | | 27535106 |
4869 | NPM1 | CLINICALLY ACTIONABLE, DNA REPAIR, DRUGGABLE GENOME, DRUG RESISTANCE | | TRETINOIN | TRETINOIN | 19965647,21719597 |
4869 | NPM1 | CLINICALLY ACTIONABLE, DNA REPAIR, DRUGGABLE GENOME, DRUG RESISTANCE | | Midostaurin | MIDOSTAURIN | |